Soliris is a first-in-class terminal complement inhibitor discovered, developed, and commercialized. Soliris works by selectively inhibiting activation of specific proteins in the complement system (C5a and C5b), which play a role in the treatment of multiple rare diseases.


There are no reviews yet.

Be the first to review “Soliris”

Your email address will not be published. Required fields are marked *